

## Supplemental table:

Table 1. Variables tested in Cox proportional hazards regression models.

---

Main effect<sup>a</sup>:

Myeloablative vs. RIC vs. NMAC

Patient-related variables:

Age at transplant: 18-29 vs. 30-39 vs. 40-49 vs. 50-59 vs.  $\geq 60$  years

Karnofsky performance status at transplant:  $\geq 90\%$  vs.  $< 90\%$  vs. missing

Disease-related:

Disease stage at diagnosis: I-II vs. III-IV vs. unknown

Symptoms at diagnosis: A vs. B vs. missing

Number of prior chemotherapy lines: 1-2 vs.  $> 2$

Rituximab prior to transplant: yes vs. no

Disease status prior to transplant: PIF-sensitive vs. PIF resistant vs. CR vs. REL sensitive vs. REL resistant vs. REL untreated/unknown vs. missing

Prior autologous: yes vs. no

Treatment-related:

Donor type: HLA identical siblings vs. HLA-matched unrelated vs. HLA-mismatched unrelated

Donor/Recipient CMV status: -/- vs. others

Donor-recipient gender match: F-M vs. others

Graf type: bone marrow vs. peripheral blood

Year of HCT: 1997-1998 vs. 1999-2001 vs. 2002-2004 vs. 2005-2007

ATG at conditioning regimen or GVHD prophylaxis: yes vs. no

---

<sup>a</sup>Included in all models.